Mildronate as a Regulator of Protein Expression in a Rat Model of Parkinson’s Disease
Material and Methods. PD was modeled by 6-hydroxydopamine (6-OHDA) unilateral intrastriatal injection in rats. Mildronate was administered at doses of 10, 20, and 50 mg/kg for 2 weeks intraperitoneally before 6-OHDA injection. Rat brains were dissected on day 28 after discontinuation of mildronate injections. The expression of biomarkers was assessed immunohistochemically and by Western blot assay.
Results. 6-OHDA decreased the expression of Hsp70 and GDNF in the lesioned striatum and substantia nigra, whereas in mildronate-pretreated (20 and 50 mg/kg) rats, the expression of Hsp70 and GDNF was close to the control group values. NCAM expression also was decreased by 6-OHDA in the striatum and it was totally protected by mildronate at a dose of 50 mg/kg. In contrast, in the substantia nigra, 6-OHDA increased the expression of NCAM, while mildronate pretreatment (20 and 50 mg/kg) reversed the 6-OHDA-induced overexpression of NCAM close to the control values.
Conclusion. The obtained data showed that mildronate was capable to regulate the expression of proteins that play a role in the homeostasis of neuro-glial processes.
Isajevs, S.; Isajeva, D.; Beitnere, U.; Jansone, B.; Kalvinsh, I.; Klusa, V. Mildronate as a Regulator of Protein Expression in a Rat Model of Parkinson’s Disease. Medicina 2011, 47, 79.
Isajevs S, Isajeva D, Beitnere U, Jansone B, Kalvinsh I, Klusa V. Mildronate as a Regulator of Protein Expression in a Rat Model of Parkinson’s Disease. Medicina. 2011; 47(10):79.Chicago/Turabian Style
Isajevs, Sergejs; Isajeva, Darja; Beitnere, Ulrika; Jansone, Baiba; Kalvinsh, Ivars; Klusa, Vija. 2011. "Mildronate as a Regulator of Protein Expression in a Rat Model of Parkinson’s Disease." Medicina 47, no. 10: 79.